

ONE HUNDRED THIRTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**

COMMITTEE ON ENERGY AND COMMERCE

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115

Majority (202) 225-2927  
Minority (202) 225-3641

July 1, 2014

Mr. Marc M. Boutin  
Executive Vice President and  
Chief Operating Officer  
National Health Council  
1730 M Street, N.W., Suite 500  
Washington, D.C. 20036

Dear Mr. Boutin:

Thank you for appearing before the Subcommittee on Health on Wednesday, June 11, 2014, to testify at the hearing entitled "21st Century Cures: Examining the Role of Incentives in Advancing Treatments and Cures for Patients."


Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

Also attached are Member requests made during the hearing. The format of your responses to these requests should follow the same format as your responses to the additional questions for the record.

To facilitate the printing of the hearing record, please respond to these questions and requests with a transmittal letter by the close of business on Wednesday, July 16, 2014. Your responses should be mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [Sydne.Harwick@mail.house.gov](mailto:Sydne.Harwick@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Joseph R. Pitts  
Chairman  
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachments

**Attachment 1—Additional Questions for the Record**

**The Honorable Michael C. Burgess**

1. Would you comment on some of the barriers that Class III medical device manufacturers face when seeking coverage and payment from CMS for innovative, cutting edge technology that improves the lives of patients?

## **Attachment 2—Member Requests for the Record**

*During the hearing, Members asked you to provide additional information for the record and you indicated that you would provide that information. For your convenience, descriptions of the requested information are provided below.*

### **The Honorable Henry A. Waxman**

1. Would you please provide the committee with the data and information to show whether there are significant numbers of dormant therapies that are waiting to be developed? Would you also please provide the data that explains why 15 years of exclusivity and patent protection are necessary for these therapies?